This study looks at a new medicine, HQP1351, for people with certain blood cancers called Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL). These are serious conditions where the blood cells grow incorrectly. The study includes people who haven't gotten better with other treatments known as tyrosine kinase inhibitors (TKIs). TKIs are a type of medicine that blocks signals cancer cells need to grow.

The study will involve about 40 patients, and participants will be given different doses of HQP1351 to find the best dose for future studies. Some patients will receive HQP1351 alone and others will receive it with another medicine called blinatumomab. The study will observe how the drug moves through the body and its effects. Participants will need to take the medicine every other day for a cycle of 28 or 42 days.

• Participants must have tried at least two other TKIs without success.
• The study will check the safety of HQP1351 and its effects.
• Participants will be monitored closely and must meet certain health criteria.